author_facet Shahedi, K.
Lindström, S.
Zheng, S.L.
Wiklund, F.
Adolfsson, J.
Sun, J.
Augustsson‐Bälter, K.
Chang, B.‐L.
Adami, H.‐O.
Liu, W.
Grönberg, H.
Xu, J.
Shahedi, K.
Lindström, S.
Zheng, S.L.
Wiklund, F.
Adolfsson, J.
Sun, J.
Augustsson‐Bälter, K.
Chang, B.‐L.
Adami, H.‐O.
Liu, W.
Grönberg, H.
Xu, J.
author Shahedi, K.
Lindström, S.
Zheng, S.L.
Wiklund, F.
Adolfsson, J.
Sun, J.
Augustsson‐Bälter, K.
Chang, B.‐L.
Adami, H.‐O.
Liu, W.
Grönberg, H.
Xu, J.
spellingShingle Shahedi, K.
Lindström, S.
Zheng, S.L.
Wiklund, F.
Adolfsson, J.
Sun, J.
Augustsson‐Bälter, K.
Chang, B.‐L.
Adami, H.‐O.
Liu, W.
Grönberg, H.
Xu, J.
International Journal of Cancer
Genetic variation in the COX‐2 gene and the association with prostate cancer risk
Cancer Research
Oncology
author_sort shahedi, k.
spelling Shahedi, K. Lindström, S. Zheng, S.L. Wiklund, F. Adolfsson, J. Sun, J. Augustsson‐Bälter, K. Chang, B.‐L. Adami, H.‐O. Liu, W. Grönberg, H. Xu, J. 0020-7136 1097-0215 Wiley Cancer Research Oncology http://dx.doi.org/10.1002/ijc.21864 <jats:title>Abstract</jats:title><jats:p>COX‐2 is a key enzyme in the conversion of arachidonic acid to prostaglandins. The prostaglandins produced by COX‐2 are involved in inflammation and pain response in different tissues in the body. Accumulating evidence from epidemiologic studies, chemical carcinogen‐induced rodent models and clinical trials indicate that COX‐2 plays a role in human carcinogenesis and is overexpressed in prostate cancer tissue. We examined whether sequence variants in the COX‐2 gene are associated with prostate cancer risk. We analyzed a large population‐based case–control study, cancer prostate in Sweden (CAPS) consisting of 1,378 cases and 782 controls. We evaluated 16 single nucleotide polymorphisms (SNPs) spanning the entire COX‐2 gene in 94 subjects of the control group. Five SNPs had a minor allele frequency of more than 5% in our study population and these were genotyped in all case patients and control subjects and gene‐specific haplotypes were constructed. A statistically significant difference in allele frequency between cases and controls was observed for 2 of the SNPs (+3100 T/G and +8365 C/T), with an odds ratio of 0.78 (95% CI = 0.64–0.96) and 0.65 (95% CI = 0.45–0.94) respectively. In the haplotype analysis, 1 haplotype carrying the variant allele from both +3100 T/G and +8365 C/T, with a population frequency of 3%, was also significantly associated with decreased risk of prostate cancer (<jats:italic>p</jats:italic> = 0.036, global simulated <jats:italic>p</jats:italic>‐value = 0.046). This study supports the hypothesis that inflammation is involved in prostate carcinogenesis and that sequence variation within the COX‐2 gene influence the risk of prostate cancer. © 2006 Wiley‐Liss, Inc.</jats:p> Genetic variation in the COX‐2 gene and the association with prostate cancer risk International Journal of Cancer
doi_str_mv 10.1002/ijc.21864
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9pamMuMjE4NjQ
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9pamMuMjE4NjQ
institution DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
imprint Wiley, 2006
imprint_str_mv Wiley, 2006
issn 1097-0215
0020-7136
issn_str_mv 1097-0215
0020-7136
language English
mega_collection Wiley (CrossRef)
match_str shahedi2006geneticvariationinthecox2geneandtheassociationwithprostatecancerrisk
publishDateSort 2006
publisher Wiley
recordtype ai
record_format ai
series International Journal of Cancer
source_id 49
title Genetic variation in the COX‐2 gene and the association with prostate cancer risk
title_unstemmed Genetic variation in the COX‐2 gene and the association with prostate cancer risk
title_full Genetic variation in the COX‐2 gene and the association with prostate cancer risk
title_fullStr Genetic variation in the COX‐2 gene and the association with prostate cancer risk
title_full_unstemmed Genetic variation in the COX‐2 gene and the association with prostate cancer risk
title_short Genetic variation in the COX‐2 gene and the association with prostate cancer risk
title_sort genetic variation in the cox‐2 gene and the association with prostate cancer risk
topic Cancer Research
Oncology
url http://dx.doi.org/10.1002/ijc.21864
publishDate 2006
physical 668-672
description <jats:title>Abstract</jats:title><jats:p>COX‐2 is a key enzyme in the conversion of arachidonic acid to prostaglandins. The prostaglandins produced by COX‐2 are involved in inflammation and pain response in different tissues in the body. Accumulating evidence from epidemiologic studies, chemical carcinogen‐induced rodent models and clinical trials indicate that COX‐2 plays a role in human carcinogenesis and is overexpressed in prostate cancer tissue. We examined whether sequence variants in the COX‐2 gene are associated with prostate cancer risk. We analyzed a large population‐based case–control study, cancer prostate in Sweden (CAPS) consisting of 1,378 cases and 782 controls. We evaluated 16 single nucleotide polymorphisms (SNPs) spanning the entire COX‐2 gene in 94 subjects of the control group. Five SNPs had a minor allele frequency of more than 5% in our study population and these were genotyped in all case patients and control subjects and gene‐specific haplotypes were constructed. A statistically significant difference in allele frequency between cases and controls was observed for 2 of the SNPs (+3100 T/G and +8365 C/T), with an odds ratio of 0.78 (95% CI = 0.64–0.96) and 0.65 (95% CI = 0.45–0.94) respectively. In the haplotype analysis, 1 haplotype carrying the variant allele from both +3100 T/G and +8365 C/T, with a population frequency of 3%, was also significantly associated with decreased risk of prostate cancer (<jats:italic>p</jats:italic> = 0.036, global simulated <jats:italic>p</jats:italic>‐value = 0.046). This study supports the hypothesis that inflammation is involved in prostate carcinogenesis and that sequence variation within the COX‐2 gene influence the risk of prostate cancer. © 2006 Wiley‐Liss, Inc.</jats:p>
container_issue 3
container_start_page 668
container_title International Journal of Cancer
container_volume 119
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792339083150753804
geogr_code not assigned
last_indexed 2024-03-01T15:41:55.454Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Genetic+variation+in+the+COX%E2%80%902+gene+and+the+association+with+prostate+cancer+risk&rft.date=2006-08-01&genre=article&issn=1097-0215&volume=119&issue=3&spage=668&epage=672&pages=668-672&jtitle=International+Journal+of+Cancer&atitle=Genetic+variation+in+the+COX%E2%80%902+gene+and+the+association+with+prostate+cancer+risk&aulast=Xu&aufirst=J.&rft_id=info%3Adoi%2F10.1002%2Fijc.21864&rft.language%5B0%5D=eng
SOLR
_version_ 1792339083150753804
author Shahedi, K., Lindström, S., Zheng, S.L., Wiklund, F., Adolfsson, J., Sun, J., Augustsson‐Bälter, K., Chang, B.‐L., Adami, H.‐O., Liu, W., Grönberg, H., Xu, J.
author_facet Shahedi, K., Lindström, S., Zheng, S.L., Wiklund, F., Adolfsson, J., Sun, J., Augustsson‐Bälter, K., Chang, B.‐L., Adami, H.‐O., Liu, W., Grönberg, H., Xu, J., Shahedi, K., Lindström, S., Zheng, S.L., Wiklund, F., Adolfsson, J., Sun, J., Augustsson‐Bälter, K., Chang, B.‐L., Adami, H.‐O., Liu, W., Grönberg, H., Xu, J.
author_sort shahedi, k.
container_issue 3
container_start_page 668
container_title International Journal of Cancer
container_volume 119
description <jats:title>Abstract</jats:title><jats:p>COX‐2 is a key enzyme in the conversion of arachidonic acid to prostaglandins. The prostaglandins produced by COX‐2 are involved in inflammation and pain response in different tissues in the body. Accumulating evidence from epidemiologic studies, chemical carcinogen‐induced rodent models and clinical trials indicate that COX‐2 plays a role in human carcinogenesis and is overexpressed in prostate cancer tissue. We examined whether sequence variants in the COX‐2 gene are associated with prostate cancer risk. We analyzed a large population‐based case–control study, cancer prostate in Sweden (CAPS) consisting of 1,378 cases and 782 controls. We evaluated 16 single nucleotide polymorphisms (SNPs) spanning the entire COX‐2 gene in 94 subjects of the control group. Five SNPs had a minor allele frequency of more than 5% in our study population and these were genotyped in all case patients and control subjects and gene‐specific haplotypes were constructed. A statistically significant difference in allele frequency between cases and controls was observed for 2 of the SNPs (+3100 T/G and +8365 C/T), with an odds ratio of 0.78 (95% CI = 0.64–0.96) and 0.65 (95% CI = 0.45–0.94) respectively. In the haplotype analysis, 1 haplotype carrying the variant allele from both +3100 T/G and +8365 C/T, with a population frequency of 3%, was also significantly associated with decreased risk of prostate cancer (<jats:italic>p</jats:italic> = 0.036, global simulated <jats:italic>p</jats:italic>‐value = 0.046). This study supports the hypothesis that inflammation is involved in prostate carcinogenesis and that sequence variation within the COX‐2 gene influence the risk of prostate cancer. © 2006 Wiley‐Liss, Inc.</jats:p>
doi_str_mv 10.1002/ijc.21864
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9pamMuMjE4NjQ
imprint Wiley, 2006
imprint_str_mv Wiley, 2006
institution DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161
issn 1097-0215, 0020-7136
issn_str_mv 1097-0215, 0020-7136
language English
last_indexed 2024-03-01T15:41:55.454Z
match_str shahedi2006geneticvariationinthecox2geneandtheassociationwithprostatecancerrisk
mega_collection Wiley (CrossRef)
physical 668-672
publishDate 2006
publishDateSort 2006
publisher Wiley
record_format ai
recordtype ai
series International Journal of Cancer
source_id 49
spelling Shahedi, K. Lindström, S. Zheng, S.L. Wiklund, F. Adolfsson, J. Sun, J. Augustsson‐Bälter, K. Chang, B.‐L. Adami, H.‐O. Liu, W. Grönberg, H. Xu, J. 0020-7136 1097-0215 Wiley Cancer Research Oncology http://dx.doi.org/10.1002/ijc.21864 <jats:title>Abstract</jats:title><jats:p>COX‐2 is a key enzyme in the conversion of arachidonic acid to prostaglandins. The prostaglandins produced by COX‐2 are involved in inflammation and pain response in different tissues in the body. Accumulating evidence from epidemiologic studies, chemical carcinogen‐induced rodent models and clinical trials indicate that COX‐2 plays a role in human carcinogenesis and is overexpressed in prostate cancer tissue. We examined whether sequence variants in the COX‐2 gene are associated with prostate cancer risk. We analyzed a large population‐based case–control study, cancer prostate in Sweden (CAPS) consisting of 1,378 cases and 782 controls. We evaluated 16 single nucleotide polymorphisms (SNPs) spanning the entire COX‐2 gene in 94 subjects of the control group. Five SNPs had a minor allele frequency of more than 5% in our study population and these were genotyped in all case patients and control subjects and gene‐specific haplotypes were constructed. A statistically significant difference in allele frequency between cases and controls was observed for 2 of the SNPs (+3100 T/G and +8365 C/T), with an odds ratio of 0.78 (95% CI = 0.64–0.96) and 0.65 (95% CI = 0.45–0.94) respectively. In the haplotype analysis, 1 haplotype carrying the variant allele from both +3100 T/G and +8365 C/T, with a population frequency of 3%, was also significantly associated with decreased risk of prostate cancer (<jats:italic>p</jats:italic> = 0.036, global simulated <jats:italic>p</jats:italic>‐value = 0.046). This study supports the hypothesis that inflammation is involved in prostate carcinogenesis and that sequence variation within the COX‐2 gene influence the risk of prostate cancer. © 2006 Wiley‐Liss, Inc.</jats:p> Genetic variation in the COX‐2 gene and the association with prostate cancer risk International Journal of Cancer
spellingShingle Shahedi, K., Lindström, S., Zheng, S.L., Wiklund, F., Adolfsson, J., Sun, J., Augustsson‐Bälter, K., Chang, B.‐L., Adami, H.‐O., Liu, W., Grönberg, H., Xu, J., International Journal of Cancer, Genetic variation in the COX‐2 gene and the association with prostate cancer risk, Cancer Research, Oncology
title Genetic variation in the COX‐2 gene and the association with prostate cancer risk
title_full Genetic variation in the COX‐2 gene and the association with prostate cancer risk
title_fullStr Genetic variation in the COX‐2 gene and the association with prostate cancer risk
title_full_unstemmed Genetic variation in the COX‐2 gene and the association with prostate cancer risk
title_short Genetic variation in the COX‐2 gene and the association with prostate cancer risk
title_sort genetic variation in the cox‐2 gene and the association with prostate cancer risk
title_unstemmed Genetic variation in the COX‐2 gene and the association with prostate cancer risk
topic Cancer Research, Oncology
url http://dx.doi.org/10.1002/ijc.21864